Research Analysts Set Expectations for HIMS FY2024 Earnings

Hims & Hers Health, Inc. (NYSE:HIMS) – Analysts at Leerink Partnrs upped their FY2024 earnings per share estimates for shares of Hims & Hers Health in a research report issued on Tuesday, October 29th. Leerink Partnrs analyst M. Cherny now expects that the company will earn $0.23 per share for the year, up from their previous forecast of $0.22. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.22 per share. Leerink Partnrs also issued estimates for Hims & Hers Health’s FY2027 earnings at $0.91 EPS.

Several other brokerages have also weighed in on HIMS. Imperial Capital lowered Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Truist Financial upped their price objective on shares of Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research note on Thursday, July 18th. Bank of America lifted their target price on Hims & Hers Health from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. TD Cowen boosted their price objective on Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, July 11th. Finally, Deutsche Bank Aktiengesellschaft lifted their target price on shares of Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a report on Wednesday, August 7th. Eight investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Hims & Hers Health currently has an average rating of “Moderate Buy” and an average target price of $20.21.

Hims & Hers Health Price Performance

NYSE:HIMS opened at $19.06 on Thursday. Hims & Hers Health has a 12 month low of $5.76 and a 12 month high of $25.74. The firm has a market capitalization of $4.09 billion, a PE ratio of 238.25 and a beta of 1.06. The business’s fifty day moving average price is $17.89 and its 200 day moving average price is $18.00.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, August 5th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.04 by $0.02. The company had revenue of $315.65 million during the quarter, compared to analysts’ expectations of $302.43 million. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The firm’s revenue was up 51.8% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.03) EPS.

Institutional Trading of Hims & Hers Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HIMS. Vanguard Group Inc. grew its holdings in shares of Hims & Hers Health by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 14,173,285 shares of the company’s stock worth $126,142,000 after buying an additional 46,541 shares in the last quarter. State of Michigan Retirement System purchased a new stake in Hims & Hers Health in the 1st quarter valued at about $2,785,000. Principal Financial Group Inc. boosted its holdings in shares of Hims & Hers Health by 17.9% in the 1st quarter. Principal Financial Group Inc. now owns 16,655 shares of the company’s stock valued at $258,000 after purchasing an additional 2,525 shares during the last quarter. Diversify Advisory Services LLC acquired a new stake in Hims & Hers Health during the first quarter worth about $701,000. Finally, Oak Ridge Investments LLC acquired a new position in shares of Hims & Hers Health in the 1st quarter valued at about $2,066,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Insider Buying and Selling at Hims & Hers Health

In other news, insider Soleil Boughton sold 2,339 shares of Hims & Hers Health stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $23.16, for a total transaction of $54,171.24. Following the completion of the transaction, the insider now owns 169,935 shares of the company’s stock, valued at $3,935,694.60. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction on Monday, August 5th. The stock was sold at an average price of $16.47, for a total transaction of $3,110,985.36. Following the completion of the transaction, the chief executive officer now owns 33,502 shares of the company’s stock, valued at approximately $551,777.94. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Soleil Boughton sold 2,339 shares of the business’s stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $23.16, for a total value of $54,171.24. Following the completion of the transaction, the insider now directly owns 169,935 shares of the company’s stock, valued at approximately $3,935,694.60. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 858,665 shares of company stock valued at $15,148,890. Insiders own 17.71% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.